These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9251329)

  • 1. Treatment of visceral leishmaniasis with a 10 day course of L-ampB-LRC (Bombay), a liposomal amphotericin B.
    Bodhe PV; Pathare AV; Kshirsagar NA; Pandya SK
    J Assoc Physicians India; 1996 Mar; 44(3):222. PubMed ID: 9251329
    [No Abstract]   [Full Text] [Related]  

  • 2. U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
    Berman JD
    Clin Infect Dis; 1999 Jan; 28(1):49-51. PubMed ID: 10391695
    [No Abstract]   [Full Text] [Related]  

  • 3. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
    Meyerhoff A
    Clin Infect Dis; 1999 Jan; 28(1):42-8; discussion 49-51. PubMed ID: 10028069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [First-line liposomal amphotericin B for pediatric visceral leishmaniasis in southern France].
    Minodier P; Robert S; Noël G; Blanc P; Retornaz K; Garnier JM
    Arch Pediatr; 2005 Jul; 12(7):1102-8. PubMed ID: 15964525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
    Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
    Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration.
    Manfredi R; Marinacci G; Calza L; Passarini B
    Int J Antimicrob Agents; 2008 Jun; 31(6):590-2. PubMed ID: 18456464
    [No Abstract]   [Full Text] [Related]  

  • 7. Amphotericin B--fat emulsion in treatment of visceral leishmaniasis--a cost effective substitute for liposomal amphotericin B.
    Singh GP; Saxena RK; Priyadarshy V
    J Indian Med Assoc; 2010 Jan; 108(1):27-8. PubMed ID: 20839576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in development of amphotericin B formulations for the treatment of visceral leishmaniasis.
    Mohamed-Ahmed AH; Brocchini S; Croft SL
    Curr Opin Infect Dis; 2012 Dec; 25(6):695-702. PubMed ID: 23147810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B (L-AmpB-LRC) in a child.
    Karande SC; Boby KF; Lahiri KR; Jain MK; Kshirsagar NA; Gokhale PC; Pandya SK
    Trop Doct; 1995 Apr; 25(2):80-1. PubMed ID: 7778200
    [No Abstract]   [Full Text] [Related]  

  • 10. A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience.
    Cascio A; di Martino L; Occorsio P; Giacchino R; Catania S; Gigliotti AR; Aiassa C; Iaria C; Giordano S; Colomba C; Polara VF; Titone L; Gradoni L; Gramiccia M; Antinori S
    J Antimicrob Chemother; 2004 Jul; 54(1):217-20. PubMed ID: 15150166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABLE: a new and improved amphotericin B for visceral leishmaniasis?
    Berman J
    Am J Trop Med Hyg; 2009 May; 80(5):689-90. PubMed ID: 19407106
    [No Abstract]   [Full Text] [Related]  

  • 12. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions.
    Sundar S; Chakravarty J; Rai VK; Agrawal N; Singh SP; Chauhan V; Murray HW
    Clin Infect Dis; 2007 Sep; 45(5):556-61. PubMed ID: 17682988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of visceral leishmaniasis with liposomal amphotericin B.
    Lagler H; Matt U; Sillaber C; Winkler S; Graninger W
    Acta Biomed; 2006; 77 Suppl 2():22-5. PubMed ID: 16918063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal amphotericin B as first line and secondary prophylactic treatment for visceral leishmaniasis in a patient infected with HIV.
    Borrelli P; Imperato A; Murdaca G; Scudeletti M
    Ann Ital Med Int; 2000; 15(2):169-71. PubMed ID: 10920508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of visceral leishmaniasis in children with liposomal amphotericin B.
    di Martino L; Davidson RN; Giacchino R; Scotti S; Raimondi F; Castagnola E; Tasso L; Cascio A; Gradoni L; Gramiccia M; Pettoello-Mantovani M; Bryceson AD
    J Pediatr; 1997 Aug; 131(2):271-7. PubMed ID: 9290615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis.
    Bodhe PV; Kotwani RN; Kirodian BG; Pathare AV; Pandey AK; Thakur CP; Kshirsagar NA
    Trans R Soc Trop Med Hyg; 1999; 93(3):314-8. PubMed ID: 10492769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute renal failure due to visceral leishmaniasis by Leishmania infantum successfully treated with a single high dose of liposomal amphotericin B.
    Beltrame A; Arzese A; Camporese A; Rorato G; Crapis M; Tarabini-Castellani G; Boscutti G; Pizzolitto S; Calianno G; Matteelli A; Di Muccio T; Gramiccia M; Viale P
    J Travel Med; 2008; 15(5):358-60. PubMed ID: 19006511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis.
    Brown M; Noursadeghi M; Boyle J; Davidson RN
    Br J Dermatol; 2005 Jul; 153(1):203-5. PubMed ID: 16029352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of visceral leishmaniasis unresponsive to pentamidine with amphotericin B.
    Mishra M
    J Assoc Physicians India; 1995 Apr; 43(4):306. PubMed ID: 8713286
    [No Abstract]   [Full Text] [Related]  

  • 20. Amphotericin B therapy in children with visceral leishmaniasis: daily vs. alternate day, a randomized trial.
    Singh UK; Prasad R; Jaiswal BP; Singh PK; Thakur CP
    J Trop Pediatr; 2010 Oct; 56(5):321-4. PubMed ID: 20065047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.